Robert Doebele's most recent trade in Boundless Bio Inc. was a trade of 180,000 Stock Option done . Disclosure was reported to the exchange on Feb. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Boundless Bio Inc. | Robert Doebele | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 180,000 | 180,000 | - | - | Stock Option | |
| Rain Oncology Inc | Robert Doebele | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 123,325 | 123,325 | - | - | Stock Option (Right to Buy) | |
| Rain Oncology Inc | Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 06 Jul 2022 | 3,890 | 476,827 | - | 4.0 | 15,366 | Common Stock |
| Rain Oncology Inc | Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2022 | 3,890 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Rain Oncology Inc | Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 13 Apr 2022 | 3,000 | 472,937 | - | 4.0 | 11,850 | Common Stock |
| Rain Oncology Inc | Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 3,000 | 8,890 | - | - | Stock Option (Right to Buy) | |
| Rain Oncology Inc | Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,000 | 11,890 | - | - | Stock Option (Right to Buy) | |
| Rain Oncology Inc | Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 31 Mar 2022 | 2,000 | 469,937 | - | 4.0 | 7,900 | Common Stock |
| Rain Oncology Inc | Robert Doebele | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Rain Oncology Inc | Robert Doebele | EVP, Chief Scientific Officer | 27 Apr 2021 | 5,327 | 0 | - | - | Series A Preferred Stock | ||
| Rain Oncology Inc | Robert Doebele | EVP, Chief Scientific Officer | 27 Apr 2021 | 4,932 | 467,937 | - | - | Common Stock |